Yinbing Tang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yinbing Tang has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Dongfang Lu
Pediatric Cancer Research Center, National Clinical Research Center for Child Health, Children’s Hospital Zhejiang University School of Medicine, Hangzhou, China
11 shared publications - Jiabin Cai
Department of Surgical Oncology, Children's Hospital Zhejiang University School of Medicine National Clinical Research Center for Children and Adolescents' Health and Diseases Hangzhou Zhejiang China
11 shared publications - Jinhu Wang
Department of Surgical Oncology, Children’s Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou, China
11 shared publications - Jinkai Peng
Pediatric Cancer Research Center, National Clinical Research Center for Child Health, Children’s Hospital Zhejiang University School of Medicine, Hangzhou, China
11 shared publications - Lifeng Zhang
Department of Oncology Surgery, Children’s Hospital, Zhejiang University School of Medicine, Hangzhou 310000, China
11 shared publications - Shouhua Zhang
Department of General Surgery, Jiangxi Provincial Children’s Hospital, The Affiliated Children’s Hospital of Nanchang Medical College, Nanchang, China
11 shared publications
Latest Publications
- Open Access
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Copy-Number Aberrations in Circulating Tumor DNA Enable Diagnosis and Risk Stratification of Pediatric Neuroblastic Tumors
Table S3. Copy-number Z-score of ctDNA samples from pNT patients and healthy controls.
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Copy-Number Aberrations in Circulating Tumor DNA Enable Diagnosis and Risk Stratification of Pediatric Neuroblastic Tumors
Table S3. Copy-number Z-score of ctDNA samples from pNT patients and healthy controls.
- Open Access
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Figure 2 from Copy-Number Aberrations in Circulating Tumor DNA Enable Diagnosis and Risk Stratification of Pediatric Neuroblastic Tumors
CNA burden in plasma ctDNA enables diagnosis and risk stratification of pNTs. A–E, TFx in various clinicopathologic groups of pNTs. Boxes indicate the median (horizontal line), 25th percentile, and 75th percentile; whiskers indicate distances from the largest and smallest value to each end of the box that are within 1.5 × box length. Values were compared with the Wilcoxon test. *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001; ns, not significant. F–H, ROC curves of the pNT-UCAD model for risk-based stratification analysis. The TFx cutoff was defined by maximizing the Youden index (sensitivity + specificity − 1) using the pROC R package. Amp, amplified; GN, ganglioneuroma; GNB, ganglioneuroblastoma; HC, healthy control; NB, neuroblastoma; non-amp, nonamplified.
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 2 from Copy-Number Aberrations in Circulating Tumor DNA Enable Diagnosis and Risk Stratification of Pediatric Neuroblastic Tumors
CNA burden in plasma ctDNA enables diagnosis and risk stratification of pNTs. A–E, TFx in various clinicopathologic groups of pNTs. Boxes indicate the median (horizontal line), 25th percentile, and 75th percentile; whiskers indicate distances from the largest and smallest value to each end of the box that are within 1.5 × box length. Values were compared with the Wilcoxon test. *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001; ns, not significant. F–H, ROC curves of the pNT-UCAD model for risk-based stratification analysis. The TFx cutoff was defined by maximizing the Youden index (sensitivity + specificity − 1) using the pROC R package. Amp, amplified; GN, ganglioneuroma; GNB, ganglioneuroblastoma; HC, healthy control; NB, neuroblastoma; non-amp, nonamplified.
- Open Access
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Table 2 from Copy-Number Aberrations in Circulating Tumor DNA Enable Diagnosis and Risk Stratification of Pediatric Neuroblastic Tumors
The diagnostic performance of pNT-UCAD evaluated based on TFx in pNTs.
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable 2 from Copy-Number Aberrations in Circulating Tumor DNA Enable Diagnosis and Risk Stratification of Pediatric Neuroblastic Tumors
The diagnostic performance of pNT-UCAD evaluated based on TFx in pNTs.
- Open Access
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Figure 1 from Copy-Number Aberrations in Circulating Tumor DNA Enable Diagnosis and Risk Stratification of Pediatric Neuroblastic Tumors
Customized pNT-UCAD workflow designed for diagnosis, risk stratification, and treatment response evaluation of pediatric neuroblastic tumor. GN, ganglioneuroma; GNB, ganglioneuroblastoma; NB, neuroblastoma.
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 1 from Copy-Number Aberrations in Circulating Tumor DNA Enable Diagnosis and Risk Stratification of Pediatric Neuroblastic Tumors
Customized pNT-UCAD workflow designed for diagnosis, risk stratification, and treatment response evaluation of pediatric neuroblastic tumor. GN, ganglioneuroma; GNB, ganglioneuroblastoma; NB, neuroblastoma.
- Open Access
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Table 1 from Copy-Number Aberrations in Circulating Tumor DNA Enable Diagnosis and Risk Stratification of Pediatric Neuroblastic Tumors
Statistical analysis of TFx between various clinicopathologic groups in pNTs.
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable 1 from Copy-Number Aberrations in Circulating Tumor DNA Enable Diagnosis and Risk Stratification of Pediatric Neuroblastic Tumors
Statistical analysis of TFx between various clinicopathologic groups in pNTs.
- Open Access
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Copy-Number Aberrations in Circulating Tumor DNA Enable Diagnosis and Risk Stratification of Pediatric Neuroblastic Tumors
Table S1. The demographic characteristics of patients.
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Copy-Number Aberrations in Circulating Tumor DNA Enable Diagnosis and Risk Stratification of Pediatric Neuroblastic Tumors
Table S1. The demographic characteristics of patients.
- Open Access
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Figure 3 from Copy-Number Aberrations in Circulating Tumor DNA Enable Diagnosis and Risk Stratification of Pediatric Neuroblastic Tumors
CIN in plasma ctDNA predicts the high-risk group in patients with pNT. A, A Heatmap of segmental alterations in ctDNA from patients with pNT. Patient information is shown at the bottom of the panel. Scale bar represents copy-number Z-score of each segment. B, Representative genome-wide copy-number variation in a healthy child (top) and a patient with pNT (bottom). C, ROC curves illustrated the diagnostic performance of chromosomal aberrations in distinguishing between healthy controls and high-risk pNTs. AUC is shown for each chromosomal aberration. D, HRD score in different risk groups of pNTs. Boxes indicate the median (horizontal line), 25th percentile, and 75th percentile; whiskers indicate distances from the largest and smallest value to each end of the box that are within 1.5 × box length. Values were compared with the Wilcoxon test. **, P < 0.01; ****, P < 0.0001; ns, not significant. Amp, amplified; GN, ganglioneuroma; GNB, ganglioneuroblastoma; HC, healthy control; NB, neuroblastoma; non-amp, nonamplified.
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 3 from Copy-Number Aberrations in Circulating Tumor DNA Enable Diagnosis and Risk Stratification of Pediatric Neuroblastic Tumors
CIN in plasma ctDNA predicts the high-risk group in patients with pNT. A, A Heatmap of segmental alterations in ctDNA from patients with pNT. Patient information is shown at the bottom of the panel. Scale bar represents copy-number Z-score of each segment. B, Representative genome-wide copy-number variation in a healthy child (top) and a patient with pNT (bottom). C, ROC curves illustrated the diagnostic performance of chromosomal aberrations in distinguishing between healthy controls and high-risk pNTs. AUC is shown for each chromosomal aberration. D, HRD score in different risk groups of pNTs. Boxes indicate the median (horizontal line), 25th percentile, and 75th percentile; whiskers indicate distances from the largest and smallest value to each end of the box that are within 1.5 × box length. Values were compared with the Wilcoxon test. **, P < 0.01; ****, P < 0.0001; ns, not significant. Amp, amplified; GN, ganglioneuroma; GNB, ganglioneuroblastoma; HC, healthy control; NB, neuroblastoma; non-amp, nonamplified.
- Open Access
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Copy-Number Aberrations in Circulating Tumor DNA Enable Diagnosis and Risk Stratification of Pediatric Neuroblastic Tumors
Table S2. The characteristics of ctDNA samples from pNT patients and healthy controls.
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Copy-Number Aberrations in Circulating Tumor DNA Enable Diagnosis and Risk Stratification of Pediatric Neuroblastic Tumors
Table S2. The characteristics of ctDNA samples from pNT patients and healthy controls.
- Open Access
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Figure 4 from Copy-Number Aberrations in Circulating Tumor DNA Enable Diagnosis and Risk Stratification of Pediatric Neuroblastic Tumors
Chemotherapy effectively reduces CNA burden in patients with pNT. A, Log10 of TFx values in 16 paired ctDNA samples collected before and after chemotherapy from the same patients. Boxes indicate the median (horizontal line), 25th percentile, and 75th percentile; whiskers indicate distances from the largest and smallest value to each end of the box that are within 1.5 × box length. Values were compared with the Wilcoxon test. ****, P < 0.0001. B, Representative genome-wide copy-number variation in patients with pNT before (top) and after (bottom) chemotherapy.
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 4 from Copy-Number Aberrations in Circulating Tumor DNA Enable Diagnosis and Risk Stratification of Pediatric Neuroblastic Tumors
Chemotherapy effectively reduces CNA burden in patients with pNT. A, Log10 of TFx values in 16 paired ctDNA samples collected before and after chemotherapy from the same patients. Boxes indicate the median (horizontal line), 25th percentile, and 75th percentile; whiskers indicate distances from the largest and smallest value to each end of the box that are within 1.5 × box length. Values were compared with the Wilcoxon test. ****, P < 0.0001. B, Representative genome-wide copy-number variation in patients with pNT before (top) and after (bottom) chemotherapy.
- Open Access
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Data from Copy-Number Aberrations in Circulating Tumor DNA Enable Diagnosis and Risk Stratification of Pediatric Neuroblastic Tumors
Low-pass whole-genome sequencing (LP-WGS) of circulating tumor DNA (ctDNA) is increasingly recognized for its utility in identifying somatic copy-number aberration (CNA). In this study, we analyzed LP-WGS ctDNA data from 73 pediatric patients with neuroblastic tumor and 11 healthy controls to explore diagnostic value of ctDNA CNA burden (including the genotypings) with a customized bioinformatics workflow. We found that a high baseline ctDNA CNA burden [tumor DNA fraction (TFx) ≥0.2%] was present in 36 of 41 patients (87.80%) with neuroblastoma, six of 22 patients (27.27%) with ganglioneuroblastoma, and three of 10 patients (30%) with ganglioneuroma. High baseline ctDNA CNA burden could predict high-risk neuroblastic tumors with an area under curve (AUC) of 0.95, sensitivity of 94.12%, and specificity of 100%. Frequent chromosomal copy-number changes, including chr17q gain, chr7 gain, chr3p loss, and chr11q loss, were found in ctDNA. Gain of chr17q demonstrated the highest diagnostic value with an AUC of 0.92, indicating strong sensitivity and specificity for detecting high-risk neuroblastic tumors. The homologous recombination deficiency score in the high- and intermediate-risk groups was significantly elevated compared with those in the low-/very low–risk group. The TFx levels and segmental alterations significantly decreased in patients with neuroblastic tumor who underwent chemotherapy, from median TFx = 13.82% before treatment to 0.24% after treatment (P < 0.0001). Our findings highlight the effectiveness of LP-WGS ctDNA CNA analysis as a promising approach for diagnosis and risk stratification of pediatric neuroblastic tumors and for monitoring chemotherapy response. Particularly, ctDNA analysis is minimally invasive, rapid, and cost-effective, which could bring additional benefits in pediatric practices.Significance:Our results support the development of ctDNA CNA analysis as a robust and minimally invasive approach for early detection, molecular diagnosis, and risk stratification of peripheral neuroblastic tumors.
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Copy-Number Aberrations in Circulating Tumor DNA Enable Diagnosis and Risk Stratification of Pediatric Neuroblastic Tumors
Low-pass whole-genome sequencing (LP-WGS) of circulating tumor DNA (ctDNA) is increasingly recognized for its utility in identifying somatic copy-number aberration (CNA). In this study, we analyzed LP-WGS ctDNA data from 73 pediatric patients with neuroblastic tumor and 11 healthy controls to explore diagnostic value of ctDNA CNA burden (including the genotypings) with a customized bioinformatics workflow. We found that a high baseline ctDNA CNA burden [tumor DNA fraction (TFx) ≥0.2%] was present in 36 of 41 patients (87.80%) with neuroblastoma, six of 22 patients (27.27%) with ganglioneuroblastoma, and three of 10 patients (30%) with ganglioneuroma. High baseline ctDNA CNA burden could predict high-risk neuroblastic tumors with an area under curve (AUC) of 0.95, sensitivity of 94.12%, and specificity of 100%. Frequent chromosomal copy-number changes, including chr17q gain, chr7 gain, chr3p loss, and chr11q loss, were found in ctDNA. Gain of chr17q demonstrated the highest diagnostic value with an AUC of 0.92, indicating strong sensitivity and specificity for detecting high-risk neuroblastic tumors. The homologous recombination deficiency score in the high- and intermediate-risk groups was significantly elevated compared with those in the low-/very low–risk group. The TFx levels and segmental alterations significantly decreased in patients with neuroblastic tumor who underwent chemotherapy, from median TFx = 13.82% before treatment to 0.24% after treatment (P < 0.0001). Our findings highlight the effectiveness of LP-WGS ctDNA CNA analysis as a promising approach for diagnosis and risk stratification of pediatric neuroblastic tumors and for monitoring chemotherapy response. Particularly, ctDNA analysis is minimally invasive, rapid, and cost-effective, which could bring additional benefits in pediatric practices.Significance:Our results support the development of ctDNA CNA analysis as a robust and minimally invasive approach for early detection, molecular diagnosis, and risk stratification of peripheral neuroblastic tumors.